Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The Company offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). It has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.
Alto Crescimento
A receita da empresa tem crescido de forma consistente nos últimos 3 anos, com média de 43.23% ano a ano.
Avaliação Justa
O PE mais recente da empresa é 51.19, em uma faixa percentil média de 3 anos.
Venda Institucional
As participações institucionais mais recentes são de 96.10M ações, uma redução de 1.93% em relação ao trimestre anterior.
Mantido por Catherine Wood
O Super Investidor Catherine Wood possui 2.21M ações desta empresa.
Alta Atividade de Mercado
A empresa tem maior interesse dos investidores, com uma taxa de giro de 20 dias de 0.50.